Skip to content
OpenCapital
Get started

King Pharmaceuticals KG Fixed Maturities, Continuous Unrealized Loss Position, Fair Value

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M—
Total equity$121.4M+2,773%
Total assets$964.2M—

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-71.3%
Enterprise value$184.93M-52.3%
P/E1.2×—
P/S1.6×-27.7×

Profitability

See full
Net margin131.5%—

Returns & leverage

See full
Return on equity90.8%—
Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept kg:FixedMaturitiesContinuousUnrealizedLossPositionFairValue.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's fixed maturities, continuous unrealized loss position, fair value.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's fixed maturities, continuous unrealized loss position, fair value?
King Pharmaceuticals (KG) reported fixed maturities, continuous unrealized loss position, fair value of $90.76M in Q1 2026.